Quoin Pharmaceuticals released a new NETHERTON NOW video featuring Kristi and her daughter Kodi, who lives with the rare genetic skin disease Netherton Syndrome. The video shares their daily challenges, including painful skin care routines and social stigma, alongside expert insights from pediatric dermatologist Dr. Moise Levy. Quoin is developing QRX003, a topical treatment currently in Phase 2/3 trials, with promising interim results and expected topline data in mid-2027. The campaign aims to raise awareness and support for patients facing this debilitating condition with no approved treatments yet.
Quoin Pharmaceuticals' NETHERTON NOW video shares a family's life with Netherton Syndrome. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 06, 2026 19:41 WIB: out of 150 priced US health stocks, 52 rose and 90 fell. Notable movers include MRNA at USD 228.67 (-5.30%), HALO at USD 117.01 (-4.84%), and SNN at USD 30.70 (-4.09%).
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
